J&J Immunotherapy Darzalex Ok’d for Expanded Combination Use – Nasdaq
|
J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use
Nasdaq Johnson & JohnsonJNJ announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's CELG multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone. The combination has been approved … |
